3Armstrong JG. Three-dimensional conformal radiotherapy: precision treatment of lung cancer [J]. Chest Surg Clin North Am, 1994, 4(1):29-43.
4Leunens G, Menten J, Weltens C, et al. Quality assessment of medical decision making in radiation oncology: variability in target volume delineation for brain turnouts [J]. Radiother Oncol, 1993, 29(2):169-175.
5Senan S, van Sornsen de Koste J, Samson M, et al. Evaluation of a target contouring protocol for 3D conformal radiotherapy in nonsmall cell lung cancer[J]. Radiother Oncol, 1999, 53(3):247-255.
6Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging [J]. Chest, 1997, 111(6): 1718-1723.
7Mountain CF. Revision in the international system for lung cancer staging[J]. Chest, 1997, 111(6):1710-1717.
8Vansteenkiste J, Stroobants S, De Leyn P, et al. Mediastinal lymph node (MLN) staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer (NSCLC): a prospective analysis of 50 cases [J]. Chest, 1997, 112(6):1480-1486.
9Logue JP, Sharrock CL, Cowan RA, et al. Clinical variability of target volume description in conformal radiotherapy planning[J]. Int J Radiat Oncol Biol Phys, 1998, 41 (4):929-931.
10Ketting CH, Austin-Seymour M, Kalet I, et al. Consistency of three-dimensional planning target volumes across physicians and institutions [J]. Int J Radiat Oncol Biol Phys, 1997, 37(2):445-453.
